Exscientia is considering an IPO , which could see the company valued at up to £ 1bn ( $ 1.31bn ) , according to Allenby Capital . The flotation could earn the company 's founder Andrew Hopkins £ 400 m . The company , which was spun out of silicon University , has used AI - based technology to significantly reduce the time and money needed to develop new drugs by analysing companies ' genetic data to identify molecules for new drugs . Exscientia 's partnerships with Roche , Sanofi , GlaxoSmithKline and Evotec could earn the company £ 320 m in upfront and milestone investments , said analyst Ian Jermin .
Exscientia is considering an IPO, which could see the company valued at up to £1bn ($1.31bn), according to Allenby Capital. The flotation could earn the company's founder Andrew Hopkins £400m. The company, which was spun out of Dundee University, has used AI-based technology to significantly reduce the time and money needed to develop new drugs by analysing patients' genetic data to identify molecules for new medicine. Exscientia's partnerships with Roche, Sanofi, GlaxoSmithKline and Evotec could earn the company £320m in upfront and milestone payments, said analyst Ian Jermin.